Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Annual Press Conference 2024
17 slides from Fresenius Medical Care's conference presentation, Feb 20, 2024
Slide 1: Annual Press Conference 2024
Helen Giza CEO & Chair of the Management Board February 20, 2024 Annual Press Conference 2024
Slide 2: Achievements: We delivered against our plan
Achievements “We delivered against our plan”
Slide 3: Care Delivery and Care Enablement: new global operating model
Care Delivery and Care Enablement: we successfully Annual Press Conference 2024 implemented our new global operating model Early access to innovation in Predictability and scale in Focus on value creation dialysis MedTech in both businesses supply chain Leverage infrastructure and global G&A Care De
Slide 4: 2023 at a glance: we delivered on our commitments
2023 at a glance: we delivered on our commitments in a year of Annual Press Conference 2024 fundamental transformation Delivered Advanced successful on New CFO and portfolio operational CD head on optimization turnaround board program through ambitions key divestments 2023 2024 Fully Executed on Sim
Slide 5: Proof points of execution in 2023
Proof points of execution in 2023 Annual Press Conference 2024 ▪ Solid revenue growth at constant currency at top end of outlook ▪ Organic growth mainly driven by favorable business development ▪ Operating income (guidance base) exceeding top end of raised outlook thanks to business growth, realized
Slide 6: Portfolio optimization: key divestments of non-core assets
Portfolio optimization: we made remarkable progress and Annual Press Conference 2024 announced key divestments of non-core and dilutive assets ▪ Closed divestments – CD and CE operations in Argentina – CD operations in Hungary – National Cardiovascular Partners (NCP), U.S. ▪ Announced divestments –
Slide 7: Group performance in 2023
Group performance in 2023: our revenue growth driven by Annual Press Conference 2024 favorable business development Revenue | guidance base1 Operating income | guidance base1 in € million Margin in % 7.8% 7.9% 8.9% 7.0% +5.5% cc +15.5%cc 19,454 in € million 19,398 305 1,741 +3.9% organic 1,512 1,540
Slide 8: Our Financials
Our Financials “Laying the foundation for sustainable profitable growth”
Slide 9: Clear prioritization of strict financial policy
Clear prioritization of strict financial policy Annual Press Conference 2024 ▪ Committed to investment grade rating and to manage net financial leverage within self-imposed range of 3.0x to 3.5x. Reduced ratio from 3.4x to 3.2x. Deleveraging ▪ Proceeds from divestments and received Tricare settlemen
Slide 10: Financial performance: we upgraded and exceeded our financial outlook
Financial performance: we upgraded and exceeded our financial Annual Press Conference 2024 outlook FY 2023 Updated Outlook FY 2023 Actuals at constant currency Low- to mid-single digit Revenue percent growth +5% FY 2022 basis: EUR 19.4bn FY 2023: EUR 20,464m Between 12 and 14 Operating income (outlo
Slide 11: FME25: accelerated savings on track to deliver EUR 650m by 2025
FME25: accelerated savings on track to deliver EUR 650m by 2025 Annual Press Conference 2024 Sustainable annual savings ▪ Transformation program introduced in 2021 and savings in € million target extended to EUR 650m by 2025 ▪ EUR 346m of sustainable savings delivered by year end 2023, while +650 p.
Slide 12: Looking ahead
Looking ahead “Building momentum on our mid-term target”
Slide 13: We stay the course on our strategic priorities
We stay the course on our strategic priorities Annual Press Conference 2024 Continued execution on accelerated and extended FME25 transformation program. Continue to follow our disciplined financial policy and ROIC focus. Further drive portfolio optimization to strengthen focus on core assets and ma
Slide 14: Setting the new standard of dialysis care through innovation
Annual Press Setting the new standard of dialysis care through innovation Conference 2024 With the 5008X Hemodialysis System, we are bringing Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S. With 100% adoption of HVHDF, mortality can be reduced by approximately (based on 2019
Slide 15: Financial outlook: accelerated earnings growth projected
Financial outlook: accelerated earnings growth projected Annual Press Conference 2024 FY 2024 Outlook Mid-term Outlook Low- to mid-single digit Revenue percent growth (outlook base) FY 2023 basis: EUR 19.0bn Group operating income margin 10% to 14% by 2025 Mid- to high-teens Operating income percent
Slide 16: High quality of care: our patients are at the center
High quality of care: our patients are at the center of everything Annual Press Conference 2024 we do Target 2025+: Partner of choice, setting the standard in kidney care with industry-leading returns Care Delivery Care Enablement Service provider of choice for Profitably shape the global dialysis p
Slide 17: Appendix / Questions and Answers
Appendix Questions and Answers
Fresenius Medical Care — Annual Press Conference 2024 on 6ix